The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia

Preeclampsia Clinical Trial

— HUGS  

Official title:

The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for Preeclampsia: a Multicenter, Open-label, Single Arm Trial, Investigator Initiated Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05287321
• Other study ID #: 2112-014-487
• Status: Recruiting
• Phase: Phase 3
• Start date: May 31, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: November 2023
• Source: Chung-Ang University Hosptial, Chung-Ang University College of Medicine
• Contact: Yoo-min Kim, MD
• Phone: +82-2-6299-1661
• Email: yoominkim[@]cau.ac.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is prospective, single arm group ,open label, and multicenter trial (with two parallel-group [Hydroxychloroquine 200mg with Aspirin 100mg or Aspirin 100mg])

Description:

This study is prospective, open label, and multicenter trial [Hydroxychloroquine 200mg with Aspirin 100mg]

The study population consists of the singleton pregnancy at high risk for preeclampsia who had adverse pregnancy outcome (preeclampsia or fetal growth restriction or intrauterine fetal death) in previous pregnancy.

After randomisation, participants are assigned to receive hydroxychloroquine 200mg with aspirin 100mg per day or aspirin 100mg per day. Treatment is initiated between 12 and 22 weeks' gestation and stopped at 36 weeks' gestation.

The medication adherence to dosing should be maintained at more than 80%.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 19 Years to 50 Years

Eligibility

Inclusion Criteria:

1. The singleton pregnant women aged from 19 to 50 years

2. Includes at least one factors of the below

? History of preeclampsia

? History of fetal growth restriction

? History of intrauterine fetal death

3. Women who have agreed to enroll in the study and given their informed consent

Exclusion Criteria:

1. Indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease and malignancy (However, the participation of the trial is allowed by the investigator based on medically necessary.)

2. Previous inclusion in other intervention study within 3 months of screening (except for non-interventional observational studies)

3. Major malformation of the fetus is diagnosed at 11-13 weeks of gestation

4. Elevated blood concentrations of creatinine more than double the normal value

5. Elevated blood concentrations of liver transaminases (AST(GOT) or ALT(GPT)) more than three times the normal value

6. Conditions related with aspirin treatment

• Previous exposure within 28 days of screening

• Previous NSAID exposure within 28 days of screening

• Bleeding disorder (von Willebrand's disease, peptic ulceration)

• Hypersensitivity to aspirin

7. Conditions related with hydroxychloroquine treatment

• Previous exposure within 28 days of screening

• Hypersensitivity to hydroxychloroquine and 4-aminoquinoline compounds

• Maculopathy

• Medications that has potential for visual disturbance

• Women who have potential for changes in the retina or visual impairment by 4-aminoquinoline compounds

• Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

• Prolonged QT interval on EKG (congenital or acquired) or The risk factors of QT prolongation (heart failure, arrhythmia, myocardial ischemia)

• Low level of potassium in the blood

• Low level of magnesium in the blood

8. Not suitable for participant based on medical evidence by investigator

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

Intervention

Drug:
• Hydroxychloroquine
Hydroxychloroquine 200mg with Aspirin 100mg

Locations

Country	Name	City	State
Korea, Republic of	Chung-Ang University Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Yoo-min Kim	Ministry of Health & Welfare, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite morbidity	Preeclampsia, Fetal growth restriction, Intrauterine fetal death, preterm delviery (<37weeks)	gestational period
Secondary	Severe preeclampsia	with severe features: severe features are uncontrolled BP (systolic BP > 160mm Hg or diastolic BP > 110mm Hg on two occasions at least 4hours apart), persistent epigastric pain, new onset headaches, pulmonary edema, thrombocytopenia (platelet count <100,000/µL), elevated liver enzymes (at twice the upper limit), impaired renal insufficiency (serum creatinine > 1.1mg/dL)	gestational period
Secondary	early preterm birth	between 23+0wks and 33+6weeks	gestational period
Secondary	Late preterm birth	delivery between 34+0 to 36+6 weeks	gestational period
Secondary	Severe Fetal growh restrection	<3% and <5% for a given gestational age	gestational period